247 related articles for article (PubMed ID: 12426976)
1. [Sinusal penetration of amoxicillin-clavulanic acid. Formulation 1 g./125 mg., twice daily versus formulation 500 mg./125 mg., three times daily].
Jehl F; Klossek JM; Peynegre R; Serrano E; Castillo L; Bobin S; Desprez D; Renault C; Neel V; Rouffiac E; Borie C
Presse Med; 2002 Oct; 31(34):1596-603. PubMed ID: 12426976
[TBL] [Abstract][Full Text] [Related]
2. Eradication of pathogens from the nasopharynx after therapy of acute maxillary sinusitis with low- or high-dose amoxicillin/clavulanic acid.
Brook I; Foote PA; Hausfeld JN
Int J Antimicrob Agents; 2005 Nov; 26(5):416-9. PubMed ID: 16226017
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic studies of amoxicillin against Streptococcus pneumoniae: comparison of a new pharmacokinetically enhanced formulation (2000 mg twice daily) with standard dosage regimens.
Odenholt I; Cars O; Löwdin E
J Antimicrob Chemother; 2004 Dec; 54(6):1062-6. PubMed ID: 15563517
[TBL] [Abstract][Full Text] [Related]
4. Outcome of treatment of respiratory tract infections due to Streptococcus pneumoniae, including drug-resistant strains, with pharmacokinetically enhanced amoxycillin/clavulanate.
File TM; Jacobs MR; Poole MD; Wynne B;
Int J Antimicrob Agents; 2002 Oct; 20(4):235-47. PubMed ID: 12385678
[TBL] [Abstract][Full Text] [Related]
5. Amoxicillin/clavulanic acid: a review of its use in the management of paediatric patients with acute otitis media.
Easton J; Noble S; Perry CM
Drugs; 2003; 63(3):311-40. PubMed ID: 12534334
[TBL] [Abstract][Full Text] [Related]
6. Bacteriological efficacy of 5-day therapy with telithromycin in acute maxillary sinusitis.
Buchanan P; Roos K; Tellier G; Rangaraju M; Leroy B
Int J Antimicrob Agents; 2005 Mar; 25(3):237-46. PubMed ID: 15737519
[TBL] [Abstract][Full Text] [Related]
7. Comparative in vitro activity of a pharmacokinetically enhanced oral formulation of amoxicillin/clavulanic acid (2000/125 mg twice daily) against 9172 respiratory isolates collected worldwide in 2000.
Koeth LM; Jacobs MR; Good CE; Bajaksouzian S; Windau A; Jakielaszek C; Saunders KA
Int J Infect Dis; 2004 Nov; 8(6):362-73. PubMed ID: 15494258
[TBL] [Abstract][Full Text] [Related]
8. Amoxicillin/clavulanate in chronic rhinosinusitis: tissue and serum distribution.
Passàli D; Mazzei T; Novelli A; Fallani S; Dentico P; Mezzedimi C; Passàli GC; Bellussi L
Acta Otorhinolaryngol Belg; 2001; 55(3):259-64. PubMed ID: 11685965
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of oral pharmacokinetically enhanced amoxycillin-clavulanate 2000/125 mg, twice daily, versus oral amoxycillin-clavulanate 1000/125 mg, three times daily, for the treatment of bacterial community-acquired pneumonia in adults.
Petitpretz P; Chidiac C; Soriano F; Garau J; Stevenson K; Rouffiac E;
Int J Antimicrob Agents; 2002 Aug; 20(2):119-29. PubMed ID: 12297361
[TBL] [Abstract][Full Text] [Related]
10. Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent.
White AR; Kaye C; Poupard J; Pypstra R; Woodnutt G; Wynne B
J Antimicrob Chemother; 2004 Jan; 53 Suppl 1():i3-20. PubMed ID: 14726431
[TBL] [Abstract][Full Text] [Related]
11. The bioavailability and pharmacokinetics of an amoxicillin-clavulanic acid granular combination after intravenous and oral administration in swine.
Sun P; Zhao T; Xiao H; Wang J; Zhang S; Cao X
J Vet Pharmacol Ther; 2021 Jan; 44(1):126-130. PubMed ID: 33063331
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamics of amoxicillin/clavulanic acid against Haemophilus influenzae in an in vitro kinetic model: a comparison of different dosage regimens including a pharmacokinetically enhanced formulation.
Löwdin E; Cars O; Odenholt I
Clin Microbiol Infect; 2002 Oct; 8(10):646-53. PubMed ID: 12390283
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of telithromycin for 5 or 10 days vs amoxicillin/clavulanic acid for 10 days in acute maxillary sinusitis.
Luterman M; Tellier G; Lasko B; Leroy B
Ear Nose Throat J; 2003 Aug; 82(8):576-80, 82-4, 586 passim. PubMed ID: 14503094
[TBL] [Abstract][Full Text] [Related]
14. Non-linear absorption pharmacokinetics of amoxicillin: consequences for dosing regimens and clinical breakpoints.
de Velde F; de Winter BC; Koch BC; van Gelder T; Mouton JW;
J Antimicrob Chemother; 2016 Oct; 71(10):2909-17. PubMed ID: 27330071
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics and dosing simulations of amoxicillin/clavulanic acid in critically ill patients.
Carlier M; Noë M; De Waele JJ; Stove V; Verstraete AG; Lipman J; Roberts JA
J Antimicrob Chemother; 2013 Nov; 68(11):2600-8. PubMed ID: 23800901
[TBL] [Abstract][Full Text] [Related]
16. Susceptibility patterns for amoxicillin/clavulanate tests mimicking the licensed formulations and pharmacokinetic relationships: do the MIC obtained with 2:1 ratio testing accurately reflect activity against beta-lactamase-producing strains of Haemophilus influenzae and Moraxella catarrhalis?
Pottumarthy S; Sader HS; Fritsche TR; Jones RN
Diagn Microbiol Infect Dis; 2005 Nov; 53(3):225-31. PubMed ID: 16257168
[TBL] [Abstract][Full Text] [Related]
17. Performance in practice: bacteriological efficacy in patients with drug-resistant S. pneumoniae.
Garau J
Clin Microbiol Infect; 2004 Apr; 10 Suppl 2():28-35. PubMed ID: 14759231
[TBL] [Abstract][Full Text] [Related]
18. Moxifloxacin versus amoxicillin clavulanate in the treatment of acute maxillary sinusitis: a primary care experience.
Rakkar S; Roberts K; Towe BF; Flores SM; Heyd A; Warner J
Int J Clin Pract; 2001 Jun; 55(5):309-15. PubMed ID: 11452678
[TBL] [Abstract][Full Text] [Related]
19. A prospective, multicentre study of moxifloxacin concentrations in the sinus mucosa tissue of patients undergoing elective surgery of the sinus.
Gehanno P; Darantière S; Dubreuil C; Chobaut JC; Bobin S; Pages JC; Renou G; Bobin F; Arvis P; Stass H
J Antimicrob Chemother; 2002 May; 49(5):821-6. PubMed ID: 12003977
[TBL] [Abstract][Full Text] [Related]
20. Extended release amoxicillin/clavulanate: optimizing a product for respiratory infections based on pharmacodynamic principles.
Jacobs MR
Expert Rev Anti Infect Ther; 2005 Jun; 3(3):353-60. PubMed ID: 15954852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
